Blood management in patients with deep prosthetic hip and knee infections.
Patients undergoing treatment for infected hip and knee replacements often have significant blood loss and require allogeneic blood transfusions. In the setting of sepsis, traditional methods of blood management such as preoperative blood donations, cell savers, and reinfusion drains are contraindicated. Pharmacologic agents can minimize transfusion requirements by increasing erythropoiesis, or minimize perioperative blood loss. This article reviews the use of these agents in the management of patients with deep prosthetic hip and knee infections.
Lee
Gwo-Chin
GC
Insall Scott Kelly Institute, New York, NY, USA.
Cushner
Fred D
FD
D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D019643:Arthroplasty, Replacement / Q000009:adverse effects*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D016459:Prosthesis-Related Infections / Q000628:therapy*; D011994:Recombinant Proteins; D012086:Reoperation
D000933:Antifibrinolytic Agents; D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa